Related Experiment Video
Updated: Jun 27, 2026
Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
Published on: November 22, 2024
Tissue Factor Pathway Inhibitor-2 (TFPI2) as a Biomarker in Gynecologic Malignancies: A Narrative Review Focusing on
Ryuji Kawaguchi1, Etsuko Miyagi2, Maehana Tomoka1
1Department of Obstetrics and Gynecology, Nara Medical University, Kashihara, Japan.
Abstract:
Tissue factor pathway inhibitor-2 (TFPI2) is a Kunitz-type serine protease inhibitor and a highly specific biomarker for gynecologic clear cell carcinomas, particularly ovarian clear cell carcinoma (CCC). This review summarizes current evidence on its roles in gynecologic malignancies, focusing on clear cell histology. A structured PubMed search was performed. English-language original articles and reviews addressing the diagnostic, prognostic, and functional roles of TFPI2 were included. Although TFPI2 is commonly silenced as a tumor suppressor in many cancers, it is consistently overexpressed in Müllerian clear cell carcinomas. Clinically, circulating TFPI2 shows high specificity for ovarian CCC, distinguishing it from other ovarian tumors and benign conditions. Its combination with cancer antigen 125 improves diagnostic sensitivity, including in early-stage disease. TFPI2 is selectively expressed in tumor cells, supporting its role as a histology-specific marker across the ovary, endometrium, and cervix. Functionally, TFPI2 may contribute to CCC biology by suppressing cell adhesion and promoting a floating dissemination phenotype. Elevated circulating TFPI2 is associated with poor outcomes in ovarian and endometrial cancers and may reflect coagulation abnormalities. It is also linked to venous thromboembolism and may improve risk stratification when combined with D-dimer. TFPI2 is a unique biomarker with diagnostic, prognostic, and biological significance, with potential applications in precision diagnostics, monitoring, and thrombosis risk assessment.
Insights
Tissue factor pathway inhibitor-2 (TFPI2) is a specific biomarker for clear cell carcinomas. Overexpressed in these cancers, TFPI2 aids in diagnosis, prognosis, and understanding cancer biology.
Area of Science:
- Gynecologic Oncology
- Biomarker Discovery
- Cancer Biology
Background:
- Tissue factor pathway inhibitor-2 (TFPI2) is a Kunitz-type serine protease inhibitor.
- TFPI2 is a highly specific biomarker for gynecologic clear cell carcinomas, especially ovarian clear cell carcinoma (CCC).
- While often a tumor suppressor, TFPI2 is overexpressed in Müllerian clear cell carcinomas.
Purpose of the Study:
- To review the diagnostic, prognostic, and functional roles of TFPI2 in gynecologic malignancies.
- To focus on TFPI2's significance in clear cell histology.
- To explore TFPI2's potential applications in clinical settings.
Main Methods:
- A structured PubMed search was conducted.
- Included English-language original articles and reviews.
- Focused on studies addressing TFPI2's diagnostic, prognostic, and functional roles.
Main Results:
- Circulating TFPI2 shows high specificity for ovarian CCC, differentiating it from other ovarian tumors and benign conditions.
- Combining TFPI2 with cancer antigen 125 enhances diagnostic sensitivity, including for early-stage disease.
- Elevated TFPI2 correlates with poor outcomes in ovarian and endometrial cancers and is linked to venous thromboembolism.
Conclusions:
- TFPI2 is a unique biomarker with significant diagnostic, prognostic, and biological implications for clear cell gynecologic cancers.
- TFPI2 aids in histology-specific diagnosis, risk stratification for venous thromboembolism, and potentially monitoring treatment response.
- Further applications of TFPI2 in precision diagnostics and thrombosis risk assessment are promising.
